Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine Priming Followed by MEC for R/R AML or High-Risk MDS
NCT01729845Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Dec 2012
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of decitabine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Fred Hutchinson Cancer Center. Started Dec 2012; status: completed.
02
Drugs
decitabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01729845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01729845.